Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
Bio-Rad实验室股票讨论区
近4年来持续有高额出售证券收益,2022年为52亿出售证券亏损,因此造成了净利润大幅超过营业利润的情况。5年平均净利为13亿。
目前市值112.5亿,如果按平均净利计算市盈率为8.6。
5年中营业利润最高为5亿,对应市盈率为22.5。
估值是高还是低取决于未来出售证券收益的规模和盈亏情况,无法判断。
暂无评论